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Abstract
Background: The homeobox gene HEX is expressed in several cell types during different phases of
animal development. It encodes for a protein localized in both the nucleus and the cytoplasm. During early
mouse development, HEX is expressed in the primitive endoderm of blastocyst. Later, HEX is expressed
in developing thyroid, liver, lung, as well as in haematopoietic progenitors and endothelial cells. Absence
of nuclear expression has been observed during neoplastic transformation of the thyroid follicular cells.
Aim of the present study was to evaluate the localization and the function of the protein HEX in normal
and tumoral breast tissues and in breast cancer cell lines.
Methods: HEX expression and nuclear localization were investigated by immunohistochemistry in normal
and cancerous breast tissue, as well as in breast cancer cell lines. HEX mRNA levels were evaluated by
real-time PCR. Effects of HEX expression on Sodium Iodide Symporter (NIS) gene promoter activity was
investigated by HeLa cell transfection.
Results: In normal breast HEX was detected both in the nucleus and in the cytoplasm. In both ductal and
lobular breast carcinomas, a great reduction of nuclear HEX was observed. In several cells from normal
breast tissue as well as in MCF-7 and T47D cell line, HEX was observed in the nucleolus. MCF-7 treatment
with all-trans retinoic acid enhanced HEX expression and induced a diffuse nuclear localization. Enhanced
HEX expression and diffuse nuclear localization were also obtained when MCF-7 cells were treated with
inhibitors of histone deacetylases such as sodium butyrate and trichostatin A. With respect to normal non-
lactating breast, the amount of nuclear HEX was greatly increased in lactating tissue. Transfection
experiments demonstrated that HEX is able to up-regulate the activity of NIS promoter.
Conclusion: Our data indicate that localization of HEX is regulated in epithelial breast cells. Since
modification of localization occurs during lactation and tumorigenesis, we suggest that HEX may play a role
in differentiation of the epithelial breast cell.
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Background
The homeobox gene HEX (known also as Prh) encodes for
a tissue-specific transcription factor that plays a role dur-
ing various phases of vertebrate development [1]. It binds
DNA in a sequence-specific manner and is able either to
activate or repress transcription of target genes [2]. During
early mouse development, HEX is first expressed in the
primitive endoderm of blastocyst and, after unilateral cell
movements, it marks the anterior visceral endoderm [3].
Later, HEX is expressed in developing thyroid, liver, lung,
as well as in haematopoietic progenitors and endothelial
cells [3,4]. Disruption of HEX gene results in embryonic
lethality due to block of early liver development [1,5].
Moreover, HEX-null mice shows defects in forebrain and
thyroid as well as in differentiation of the monocyte line-
age. Although HEX is primarily known as a transcriptional
regulator [6], in several situations HEX is localized prima-
rily in the cytoplasm. For example, HEX localization is
nuclear in endodermal cells that give rise to the liver,
while it is cytoplasmic in cells lateral to the liver-forming
region [7]. Moreover, in malignant thyroid tumors, HEX
expression is confined to the cytoplasm only [8]. Accord-
ingly, it has been demonstrated that HEX is able to inter-
act with factors that have cytoplasmic functions such as
proteasome proteins [9] and eIF4E [10]. Misexpression of
HEX gene may have a causal role in neoplastic cell prolif-
eration. In fact, HEX overexpression in haemopoietic pre-
cursor cells promotes development of T-cell-derived
lymphomas [11]. It has recently been shown that HEX
protein is transiently expressed during development of
skin and that its overexpression in dermal fibroblasts
stimulates proliferation of epidermal cells [12]. Thus,
most likely, HEX gene is expressed and plays a functional
role in several additional cell types beyond those identi-
fied in early investigations.
Breast cancer is the leading cause of cancer death in
women worldwide [13]. A better understanding of the
molecular mechanisms involved in breast cancer forma-
tion and progression is therefore of crucial importance. To
date, no studies have been carried out to evaluate the role
of HEX gene in breast cells. In the present study, we have
investigated the expression of HEX protein in normal and
cancerous breast tissue as well in breast cancer cell lines.
Methods
Tissue samples and cell lines
The present study included: 9 normal, non-lactating
breast tissues; 3 lactating breast tissues; 14 ductal breast
carcinomas and 6 lobular breast carcinomas. Donor
patients received no preoperativechemotherapy or hor-
monotherapy. MCF-7 and T47D cell lines were cultured in
DMEM supplemented with 10% fetal bovine serum
(Gibco). HBL 100 cell line was cultured in RPMI with
10% fetal bovine serum (Gibco). The study was con-
ducted in accordance with the tenets of the Declaration of
Helsinki. Following the indication of Italian DLgs no.
196/03 (Codex on Privacy) a written consent was
obtained from all patients.
Immunohistochemistry
Formalin-fixed, paraffin-embedded samples were evalu-
ated for the expression of HEX protein using an immu-
noperoxidase technique. Sections of formalin-fixed,
paraffin embedded representative blocks of breast cancer
were cut onto silane-coated slides and dewaxed. After
blocking of endogenous peroxidase, sections were incu-
bated with rabbit antiserum to HEX diluted 1:250 in PBS
overnight at 4°C. After washing, the peroxidase EnVision
System (HPR rabbit/Mouse Envision System TM, Dako-
Cytomation, Denmark) was applied for 30 min at room
temperature. Peroxidase activity was detected with 3,3'-
diaminobenzidine tetrachloride (Sigma) and haematoxy-
lin counterstain. Negative controls were carried out by
replacing the primary antiserum with pre-immune rabbit
serum. The HeLa cell line, which does not expresses HEX
[14], has been used as negative control. The specificity of
antiserum to HEX was previously described [8]. A brown
staining in the nucleus and/or in the cytoplasm indicated
the presence of HEX protein. The HEX expression was
evaluated calculating separately nuclear and cytoplasmic
reactivity in 1000 cells, and was expressed as a percentage
of positive cells. In breast cancer samples an immunohis-
tochemical evaluation of oestrogen and progesterone
receptors (1D5 and 636 clone, DakoCytomation, Den-
mark) and proliferation fraction with ki-67 (MIB-1 clone
DakoCytomation, Denmark) was done and expressed as
percentage of positive nuclei. In the case of cell cultures
(see below), cells were immediately fixed with ethanol
containing 5% glacial acetic acid for 10 min at 4°C, and
rinsed with 0.1% saponin (Sigma Chemical Co., St Louis,
MO, USA) in PBS. This PBS-saponin solution was also
used for all subsequent washing steps. The cultures were
incubated overnight at 4°C with rabbit antiserum to HEX
diluted 1:100. After washing, the peroxidase EnVision Sys-
tem (HPR rabbit/Mouse Envision System TM, DakoCyto-
mation, Denmark) was applied for 30 min at room
temperature.
Phosphatase alkaline was developed with new fuchsin
(Fuchsin + substrate - Chromogen, Dako, Denmark) con-
taining levamisole. Control staining used pre-immune
rabbit serum (Dako A/S, Denmark) instead of the primary
antiserum.
Real-time PCR
Quantitative PCR analysis of HEX mRNA expression was
performed as previously described [15]. Briefly, total RNA
was extracted with RNeasy protect mini kit (Qiagen). 1 μg
of total RNA was reverse-transcribed to single strandBMC Cancer 2006, 6:192 http://www.biomedcentral.com/1471-2407/6/192
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cDNA using random exaprimers and 200 U of Superscript
II reverse transcriptase (Invitrogen, Milan, Italy) in a final
volume of 20 μl, at 42°C for 50 min followed by heating
at 70°C for 15 min.
Real time PCR reactions were performed using the ABI
Prism 7300 Sequence Detection System (Applied Biosys-
tems, Foster City, CA, USA). Oligonucleotide primers and
probes for HEX were purchased from Applied Biosystems
as Assays-on-Demand Gene Expression Products. Oligo-
nucleotide primers and probe for the endogenous con-
trols Abelson (ABL), Beta-glucuronidase (GUS) and Beta-
2-microglobulin (B2M) are described by Beillard et al.
[16]. A 25 μl reaction mixture containing 5 μl of cDNA
template, 12.5 μl TaqMan Universal PCR master mix
(Applied Biosystems) and 1.25 μl primer probe mixture
was amplified using the following thermal cycler parame-
ters: incubation at 50°C for 2 min and denaturation at
95°C for 10 min, then 40 cycles of the amplification step
(denaturation at 95°C for 15 sec and annealing/extension
at 60°C for 1 min). The ΔCT method, by means of the SDS
software (Applied Biosystem), was used to calculate the
mRNA levels.
Cell transfection
The Sodium Iodide Symporter (NIS) gene promoter activ-
ity was investigated by using a clone, kindly provided by
U. Loos (University of Ulm, Germany), containing 2.2 Kb
of 5' genomic sequence for the NIS promoter, containing
the minimal promoter linked to the luciferase (LUC) gene
as reporter [17,18]. The HEX and PAX8 expression vector
have been previously described [14,19].
The transfection efficiency was normalized by cotransfect-
ing the CMV-βGAL plasmid, which contains the Cytome-
galovirus (CMV) promoter linked to the β-galactosidase
(βGAL) gene.
The calcium phosphate co-precipitation method used for
transfections was performed as previously described [20].
HeLa cells were plated at 6 × 105 cells/100-mm culture
dish 20 hours prior to transfection. Plasmids were used in
the following amount per dish: CMV-βGAL, 2 μg; pNIS-
LUC, 7 μg; HEX expression vector 1 μg and 2 μg, PAX8
expression vector 1 μg and 2 μg. In both HEX and PAX8
expression vectors transcription is driven by the CMV pro-
moter. An empty vector containing the CMV promoter has
been cotransfected with the reduced amount of the HEX
and PAX8 expression vectors to avoid squelching effects.
Cells were harvested 44 hours after transfection and cell
extracts were prepared by a standard freeze-and-thaw pro-
cedure.  βGAL protein was measured by ELISA method
(Amersham Pharmacia Biotech, Milan, Italy). LUC activ-
ity was measured by a standard chemiluminescence pro-
cedure [21].
Statistical analysis
Spearman's Correlation Coefficient Rho was used as a
non-parametric measure of correlation between two ordi-
nal variables. Statistical significancy was expressed as p <
0.05. Mann-Whitney and Kruskal-Wallis were performed
as nonparametric alternatives to the one-way analysis of
variance. Both tests look for differences among the popu-
lations medians.
Results
HEX expression was first evaluated by immunohisto-
chemistry in 9 samples of normal breast tissue. As shown
in panel A and B of Fig. 1, HEX was expressed in normal
mammary gland. In particular, it was expressed in epithe-
lial cells of the terminal duct-lobular unit. HEX was pre-
dominantly present in the cytoplasm with only a fraction
HEX expression and localization in normal tissues, breast  carcinomas and cell lines Figure 1
HEX expression and localization in normal tissues, breast 
carcinomas and cell lines. Immunohistochemical analysis was 
performed as described in the methods section. A and B: 
normal breast tissue. C: ductal carcinoma. D: lobular carci-
noma. E: MCF-7 cells. F: T47D cells. G: HBL100 cells stained 
with p63 and CD10. H: HBL100 cells stained with HEX.BMC Cancer 2006, 6:192 http://www.biomedcentral.com/1471-2407/6/192
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of cells showing nuclear staining. In several epithelial cells
a nucleolar reactivity was evident.
HEX expression in ductal and lobular breast carcinomas is
shown in panels C and D of Fig. 1. The main characteris-
tics of the analysed tumour samples are shown in Tab. 1
In breast carcinomas, HEX was mainly expressed in cyto-
plasm (median percentage of reactive cells: 70; 25th–75th
percentiles: 40–90) than in nucleus (median percentage
of reactive cells: 0; 25th–75th percentiles: 0–1.15). No sig-
nificant differences were observed in terms of HEX nuclear
or cytoplasmic staining intensity among the different
areas of each tumour. Moreover, no staining intensity dif-
ferences were observed among the different tumour sam-
ples. A significant difference between normal and cancer
tissues, in terms of HEX nuclear reactivity, was present
(Tab 2). According to the histotype, the nuclear HEX
expression was higher in lobular (median 1.25%; 25th–
75th percentiles 0.6–2.1%) than in ductal (median 0%;
25th–75th  percentiles 0–0%) invasive carcinomas (p =
0.023). Higher expression of nuclear HEX was observed in
grade 2 tumors than in the other grade categories (p =
0.05). This observation can be because all lobular carcino-
mas were grade 2. In fact, by excluding lobular invasive
cancer from the analysis, no statistically significant associ-
ation was found between grade and HEX nuclear staining
(p = 0.7).
A correlation between HEX cytoplasmic expression and
proliferative activity, evaluated by MIB-1 immunohisto-
chemistry, just failed to reach significance (rho: 0.4, p =
0.07). A statistically significant direct correlation was
found between estrogen receptor and HEX nuclear expres-
sion (rho = 0.6, p = 0.004). No statistically significant cor-
relation was observed between HEX cytoplasmic staining
and estrogen receptor expression (rho = 0.2, p = 0.25). In
addition, there was a trend in favour of an inverse correla-
tion between progesterone receptor expression and HEX
cytoplasmic expression (rho: – 0.3, p = 0.09). No signifi-
cant correlation was found between nuclear HEX staining
and progesterone receptor expression (rho = -0.1, p = 0.9).
HEX expression was also investigated in mammary
tumour cell lines. MCF-7 cells showed weak staining. In
the nucleus, HEX was present predominantly at nucleolus
level (Fig. 1, panel E). An evident nucleolar HEX localiza-
tion was observed also in T47D cell line; in this cell line
the cytoplasmic expression of HEX was more evident than
that observed in MCF-7 cells (Fig. 1, panel F).
HBL100 are cells of myoepithelial origin [22]. In agree-
ment to this notion, this line expressed well known mark-
ers of myoepithelial cells: p63 (in the nucleus) and CD10
(in the plasma membrane) (Fig. 1, panel G). HBL100 cells
expressed HEX neither in the cytoplasm nor in the nucleus
(Fig. 1, panel H). Altogether, these data would suggest that
in mammary tissue HEX is expressed in epithelial and not
in myoepithelial lineages.
It has been recently demonstrated that in a vitamin-A defi-
cient animal model, which lacks biologically active retin-
oic acid (RA), HEX expression is affected [23]. Thus, we
tested whether RA is able to modify HEX expression/com-
partimentalization. MCF-7 cells were treated with all-trans
RA (ATRA) for 15 hours at the concentration of 1 μM and
HEX expression and localization was evaluated by immu-
nohistochemistry. Fig. 2 (Panels A and B) shows that in
the absence of ATRA a nucleolar positivity was preminent.
The ATRA treatment induced an intense and diffuse
nuclear positivity. Since differences between ATRA-treated
and untreated cells were extremely evident, the time-
course of ATRA action was assessed by measuring the per-
centage of cells with intense and diffuse nuclear localiza-
tion with respect to those with only nucleolar positivity.
As shown in panel C of Fig. 2, the effect of 1 μM ATRA was
already evident after 4 hours treatment. In order to cor-
roborate immunohistochemical data, HEX mRNA levels
in MCF-7 cells were evaluated by real-time PCR before
and after 1 μM ATRA treatment. As shown in panel D of
Fig. 2, HEX mRNA levels increased upon ATRA treatment;
as in the immunohistochemical assay, the ATRA effect was
already evident after 4 hours treatment.
Retinoids induce lumen morphogenesis in mammary epi-
thelial cells [24]. Moreover, modification of HEX compar-
timentalization during differentiation has been
previously observed [7]. Therefore, since the maximal dif-
ferentiation state of the breast occurs during lactation, we
tested the hypothesis that HEX nuclear localization could
be modified in lactating mammary gland. HEX expression
of five cases of non-lactating breast tissues and three cases
of lactating breast tissues was assessed by immunohisto-
chemistry in the same experiment. As shown in Fig. 3, the
nuclear localization of HEX was greatly increased in nuclei
of lactating breast cells. No significant differences were
observed among the different cases of lactating breasts.
These data suggest that HEX may play a role in controlling
genes whose expression is modified during lactation.
The gene encoding NIS is expressed in mammary gland
only during lactation [25]. Therefore, in order to assign a
biological role to increased HEX nuclear localization dur-
ing lactation, we tested whether HEX was able to activate
NIS promoter. HeLa cells (which do not express the HEX
gene), [14] were transfected with a construct containing
the human NIS promoter linked to the LUC gene, either
in presence or absence of expression vectors for HEX or
PAX8. This latter is a known activator of NIS expression
[19,26]. As shown in Fig. 4, the presence of HEX was asso-
ciated to an increase of the NIS promoter activity, with aBMC Cancer 2006, 6:192 http://www.biomedcentral.com/1471-2407/6/192
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significant effect already at 1 μg of expression vector (p <
0.01, according to the Student's T test). The HEX effect was
similar to that induced by PAX8 both at 1 and 2 μg. Thus,
the overexpression of NIS during lactation could be, at
least in part, due to the increase and relocalization of
HEX.
We recently reported that histone deacetylase (HDAC)
inhibitors such as sodium butyrate (NaB) and trichostatin
A (TSA) are able to increase NIS expression in MCF-7 cells
[15]. Thus, in order to support the role of HEX in the con-
trol of NIS expression, MCF-7 cells were treated with NaB
(3 mM) and TSA (300 nM) for 30 hours and subjected to
Effects of ATRA on HEX expression and localization in MCF-7 cells Figure 2
Effects of ATRA on HEX expression and localization in MCF-7 cells. HEX protein and HEX mRNA levels were evaluated by 
immunohistochemistry and real time PCR, respectively. A: untreated MCF-7 cells. B: MCF-7 cells treated for 15 hours with 
ATRA 1 μM. C: time-course of ATRA effect on HEX localization. Each square represents the mean value ± standard deviation 
of four 100 cells counts in different slides. D: time-course of ATRA effect on HEX mRNA levels. Each dot represents the mean 
value ± standard deviation of three independent determinations.
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HEX nuclear localization in lactating breast Figure 3
HEX nuclear localization in lactating breast. Panel A: non-lactating tissue. Panel B: lactating tissue. Panel C: quantification of the 
HEX nuclear positivity in non-lactating and lactating breast tissues. HEX nuclear positivity was evaluated by calculating sepa-
rately nuclear and cytoplasmic reactivity in 1000 cells. Each bar represents the mean value ± standard deviation of nuclear 
HEX, expressed as percentage of stained cells in the nucleus.
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real-time PCR and immunohistochemistry. Both com-
pounds induced a diffuse nuclear localization, which was
superimposable to that observed upon ATRA treatment
(data not shown). As shown in Fig. 5, either compound
increases HEX mRNA levels as well as the HEX diffuse
nuclear localization. Therefore, the increase of NIS expres-
sion when MCF-7 cells are treated with NaB and TSA [15],
is associated to the increase of HEX expression and of its
diffuse nuclear localization, supporting the existence of a
functional link between HEX and NIS in breast cells.
Discussion
In this study we investigated the expression of HEX in nor-
mal and tumoral breast tissues as well as in breast cancer
cell lines. As in other tissues, HEX is present both in
nucleus and cytoplasm. In breast cells, however, it is
extremely clear that, at the nuclear level, HEX is particu-
larly evident in the nucleolus. Nucleoli are organelles
within the nucleus that are assembled around clusters of
tandemly repeated ribosomal genes (rDNA) [27]. They
seem to be predominantly involved in ribosome biogen-
esis. There is, however, increasing evidence that nucleoli
also have non-ribosomal functions, such as being the site
for protein synthesis [28] and being involved in the regu-
lation of proteins such as the tumor suppressor gene p53
[29], the proto-oncogene c-myc [30] and HIV-regulatory
proteins [31,32]. It has been recently demonstrated that
activation of HIF occurs by pH-dependent nucleolar
sequestration of VHL [33]. Thus, the nucleolar localiza-
tion of HEX, together with the cytoplasmic localization,
could be part of a control mechanism to sequestrate HEX
protein from its target genes.
Another interesting observation is that HEX nuclear local-
ization is reduced in cancer cells. A similar phenomenon
(decrease of HEX nuclear expression in cancer compared
to normal tissue) has been previously observed in thyroid
tumours [8]. These data suggest that the decrease of
nuclear HEX in cell transformation could be a common
phenomenon for tumours originating from HEX-express-
ing tissues. The decrease of HEX nuclear localization in
tumours suggests that HEX compartimentalization could
be related to the differentiation state of the cell. Accord-
ingly, HEX nuclear localization is greatly increased during
lactation.
HEX nuclear localization is greatly increased in lactating
breast tissues and in MCF-7 cells treated with ATRA.
Effects of vitamin-A deficiency on breast function and
development are well documented. In rats, low vitamin-A
intake affects expression of iron transporters and milk
iron levels [34]. Vitamin-A deficient female mice show
reduced ductal and lobular alveolar development and
decrease of secretory activity [35]. Moreover, by using "in
vitro" systems, it has been shown that RA promotes lumen
formation by mammary epithelial cells [24]. It could be
hypothesized, therefore, that nuclear HEX may play a role
in breast cell differentiation and that this transcription
factor is part of the molecular pathway by which RA con-
trols development and function of the mammary gland.
We report several evidences indicating that the nuclear
HEX levels may control NIS expression. First, HEX is able
to activate the human NIS promoter at a similar extend of
PAX8, which is a known activator of NIS expression
[19,26]. Second, treatment of MCF-7 cells with 1 μM
HEX effects on NIS promoter Figure 4
HEX effects on NIS promoter. HeLa cells were transfected 
with 1 and 2 μg of the HEX or PAX8 expression vector 
together with plasmids containing the NIS and the CMV pro-
moters linked to the LUC and the βGAL reporter genes, 
respectively. The CMV-βGAL plasmid was used to normalize 
for efficiency of transfection. Each dot represents the mean 
value ± standard deviation of four independent transfections. 
Results are expressed as percentage of the values obtained in 
cells not transfected with HEX or PAX8 expression vectors.
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ATRA for 4 and 8 hours increases HEX expression and
induces a diffuse nuclear localization. This effect fits per-
fectly well to the data reported by Kogai et al [36], which
show that 1 μM ATRA treatment of MCF-7 cells induces
Effects of HDAC inhibitors on HEX expression and nuclear localization in MCF-7 cells Figure 5
Effects of HDAC inhibitors on HEX expression and nuclear localization in MCF-7 cells. Cells were treated for 30 hours with 
NaB (3 mM) and TSA (300 nM). Then, HEX mRNA levels were evaluated by real-time PCR and HEX localization by immuno-
histochemistry. Panel A: effect of NaB and TSA on HEX mRNA levels. Panle B: effect of NaB and TSA on the HEX diffuse 
nuclear localization. In both panels each bar represents the mean value ± standard deviation of three independent measures. In 
both panels, according the paired Student's T test, the differences between treated and untreated cells were highly significant 
(at least: p < 0.01).
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Table 1: Characteristics of tumour samples
Characteristic N° %
Histotype:
Ductal 14 70
Lobular 6 30
Grade:
15 2 5
21 0 5 0
35 2 5
Hormonal receptor status:
ER*positive 16 80
ER negative 4 20
PGR positive 11 55
PGR negative 9 45
HEX expression:
Nuclear 7 35
Cytoplasmic 20 100
*: ER, Estrogen receptor; PGR, Progesterone receptor.
Positive samples were considered when specific staining was present in ≥ 10% of cells.BMC Cancer 2006, 6:192 http://www.biomedcentral.com/1471-2407/6/192
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increase of NIS expression, with HEX mRNA peaking after
12 hours. Third, treatment of MCF-7 cells with HDAC
inhibitors induces HEX expression and its diffuse nuclear
localization (see Fig. 5) as well as NIS expression [15]. It
should pointed out, however, that the nuclear HEX is
decreased in breast tumours, even though NIS is expressed
[37]. It is possible that transcription factors different than
HEX may contribute to NIS expression in breast tumours.
In fact, it has been recently demonstrated that the tran-
scription factor Nkx-2.5 is expressed in human breast can-
cer cells and is able to induce NIS expression [38]. HEX is
expressed in thyroid follicular cells [14], therefore it may
play a role in the control of NIS expression also in that cell
type. The decrease of HEX nuclear localization that occurs
in thyroid cancer cells [8], may contribute to the decrease
of NIS expression that occurs in these neoplasms. Expres-
sion of the endogenous NIS gene in breast cancer may
have a therapeutical relevance. In fact, NIS is responsible
for uptake of iodide into cells. The presence of NIS in the
basolateral membrane of thyroid follicular cells has been
exploited for many years with the use of radioiodine to
treat thyroid disease. The use of radiodine has proven to
be a safe and effective way for imaging and treatment of
thyroid cancer [39]. The finding that NIS gene is expressed
in tissues other than the thyroid, has raised the possibility
of using radioiodide for imaging and treatment of tumors
of nonthyroid origin [40]. Our results may contribute to
understand how to increase NIS expression in breast can-
cer.
Conclusion
We have investigated the expression of HEX gene in
human breast: as in other tissues, HEX is localized both in
the nucleus and in the cytoplasm. HEX nuclear expression
is down-regulated in breast cancer whilst it is up-regulated
during lactation. In several cells from normal breast tissue
as well as in MCF-7 and T47D cell line, HEX was observed
in the nucleolus. Treatment of MCF-7 cells with ATRA
increases both HEX expression and nuclear localization of
the protein. These data indicate that localization of HEX is
regulated in epithelial breast cells. Since modification of
localization occurs during lactation and tumorigenesis,
and is elicited by differentiation inducers, we suggest that
HEX may play a role in differentiation of the epithelial
breast cell. Data suggesting that HEX is able to increase the
NIS promoter activity may indicate a molecular mecha-
nism that could be potentially utilized to increase the
expression of the endogenous NIS gene in breast cancer
cells.
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